Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and Iron Deficiency Anemia

Highly Statistically Significant Differences Observed in Serum Phosphorus, TSAT, Ferritin, Hemoglobin and FGF-23 versus Placebo

Conference Call to Be Held Today, November 5, 2013, at 8:30 am Eastern Time

  Keryx Biopharmaceuticals, Inc. (KERX) today announced successful top-line results from its Phase 2 study of Zerenex(TM) (ferric citrate coordination complex) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and iron deficiency anemia. In this study, Zerenex met both co-primary endpoints, described below, demonstrating highly statistically significant changes in serum phosphorus and transferrin saturation (TSAT) versus placebo over the 12-week treatment period.

Read more: Keryx Biopharmaceuticals Inc ( KERX )

Cytori Licenses Asia-Pacific Cardiovascular, Renal & Diabetes Markets to Lorem Vascular for up to $531 Million

Cytori to Receive $31 Million Upfront in Equity and Initial Purchase Commitments

Cytori Therapeutics (CYTX) and Lorem Vascular today announced a partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia. Under the agreement, Lorem Vascular committed to pay up to $531 million in license fees, opening product purchase commitments and Cytori equity purchases. Cytori Cell Therapy is derived from the Company’s Celution® System, which enables access to a patient’s own adipose-derived regenerative cells (ADRCs) at the point-of-care.

Read more: Cytori Therapeutics ( CYTX )

Covalon Announces Major License and Distribution Agreement with Molnlycke Health Care

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV.V), an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care ("Molnlycke").

Under the license agreement, Covalon has granted Molnlycke the exclusive rights to exploit Covalon's patent-pending antimicrobial silicone adhesive technology in the field of single-use surgical, wound care and vascular access medical dressings.

Covalon will receive $3.5 million in upfront license fees and additional ongoing minimum royalties, milestone payments and other fees.  Covalon retains the rights to exploit the antimicrobial silicone adhesive technology in other fields and commercialize new life-saving products in its development pipeline while continuing to distribute its other products.

Read more: Covalon Technologies Ltd ( COV )

Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability

"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Patients"

Resverlogix Corp. (TSX:RVX) today announced two additional results from the ongoing analysis of its Phase 2b ASSURE clinical trial using intravascular ultrasound (IVUS) to study high-risk cardiovascular disease (CVD) patients for assessing benefits of RVX-208.  This lead molecule is a member of a new class of compounds that affects cellular epigenetics by specifically inhibiting a BET protein leading to enhanced apoA-I gene transcription and the creation of functional HDL particles for treating atherosclerotic CVD.  Since the completion of the ASSURE trial the continued analysis of the data have yielded two new findings that detail the effects of RVX-208 on vascular inflammation and virtual histology.

Read more: Resverlogix Corp ( RVX )

Lorus to Focus LOR-253 Development on AML Based on Genetic Insights Into the Causes of Certain Hematologic Cancers

Silencing of the KLF4 Tumor Suppressor by CDX2 is a Critical Oncogenic Event in AML; LOR-253 Can Reactivate the Silenced KLF4 Gene Brian Druker, M.D. Appointed Chair of the Newly-Formed Scientific Advisory Board

Lorus Therapeutics Inc.  (LOR ) (Lorus), announced today that the company will pursue the clinical development of LOR-253, its first-in-class, small molecule inducer of the tumor suppressor Krüppel-like factor 4 (KLF4), in acute myeloid leukemia (AML) and other hematologic malignancies.

Read more: Lorus Therapeutics Inc ( LOR )